Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHTNING: Real-time Margin Assessment in Head and Neck Cancer
NCT05499065Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2023
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab-IRDye 800CW in head and neck squamous cell carcinoma (HNSCC), sponsored by University Medical Center Groningen. Started Mar 2023; status: completed.
02
Drugs
cetuximab-IRDye 800CW
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05499065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05499065.